Benjamin J. Hindson Ph.D.
Net Worth
Last updated:
What is Benjamin J. Hindson Ph.D. net worth?
The estimated net worth of Dr. Benjamin J. Hindson Ph.D. is at least $83,111,956 as of 22 Nov 2024. He owns shares worth $4,567,672 as insider, has earned $75,469,434 from insider trading and has received compensation worth at least $3,074,850 in 10x Genomics, Inc..
What is the salary of Benjamin J. Hindson Ph.D.?
Dr. Benjamin J. Hindson Ph.D. salary is $614,970 per year as Co-Founder, Pres, Chief Scientific Officer & Director in 10x Genomics, Inc..
How old is Benjamin J. Hindson Ph.D.?
Dr. Benjamin J. Hindson Ph.D. is 50 years old, born in 1975.
What stocks does Benjamin J. Hindson Ph.D. currently own?
As insider, Dr. Benjamin J. Hindson Ph.D. owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
10x Genomics, Inc. (TXG) | Co-Founder, Pres, Chief Scientific Officer & Director | 339,897 | $13.44 | $4,567,672 |
What does 10x Genomics, Inc. do?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Benjamin J. Hindson Ph.D. insider trading
10x Genomics, Inc.
Dr. Benjamin J. Hindson Ph.D. has made 50 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 5,807 units of TXG stock worth $79,486 on 22 Nov 2024.
The largest trade he's ever made was exercising 113,920 units of TXG stock on 28 Dec 2021. As of 22 Nov 2024 he still owns at least 339,897 units of TXG stock.
10x Genomics key executives
10x Genomics, Inc. executives and other stock owners filed with the SEC:
- Dr. Benjamin J. Hindson Ph.D. (50) Co-Founder, Pres, Chief Scientific Officer & Director
- Dr. Serge Saxonov Ph.D. (48) Co-Founder, Chief Executive Officer & Director
- Mr. Bradford J. Crutchfield (62) Chief Commercial Officer
- Mr. Justin J. McAnear (49) Chief Financial Officer
- Ms. Ruth De Backer (48) Chief Bus. Officer